1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EA60ECE5ABB117046525790B003CB683
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/product-launch-resource-allocation-investment-requirements-timing?opendocument
18
19opendocument
2034.229.151.87
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Resource Allocation and Launch Readiness Factors that Shape a Strong Oncology Market Entry: Stakeholder Allocations, Investment Levels and Resource Levels Across Launch Functions

ID: 5158


Features:

13 Info Graphics

13 Data Graphics

114 Metrics

8 Narratives


Pages/Slides: 34


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Resource Allocation and Launch Readiness Factors that Shape a Strong Oncology Market Entry: Stakeholder Allocations, Investment Levels and Resource Levels Across Launch Functions"

STUDY OVERVIEW

One of the more difficult aspects of planning a new oncology product launch is balancing the different resource and investment allocations that are needed to prepare the marketplace for a new product. In particular, organizations wrestle with allocating the appropriate resources for informing key stakeholders as well as other critical launch activities that are carried out across different functional areas.

This Best Practices, LLC study reviews key resource and investment benchmarks regarding a new oncology product launch, such as percentage of resources for educating stakeholder groups, investment requirements for entering a competitive marketplace, and rating the importance of using launch resources for key activities carried out across different groups such as R&D, Medical Affairs, Marketing, Sales, and Supply Chain. In addition, the study also looks at current and future trends in resource allocation. Executives and managers in oncology product launch groups can use this study to compare their current launch resource and allocation approaches with those at leading companies. This study presents two segments: an oncology segment and a total benchmark class segment.

KEY TOPICS

  • Resource Allocation for Key Stakeholders in the Current & Future Marketplaces
  • Investment Requirements, Resource Allocation & Timing
  • Internal Launch Readiness

SAMPLE METRICS

  • Percentage of resources allocated for education activities targeting key stakeholder groups, current and future
  • Level of investment required for a new product to successfully enter a crowded marketplace
  • Percentage of market preparation investment allocated for key constituencies during three periods leading up to launch
  • Level of importance of different Clinical Operations/ R&D resources/approaches for successful new product entry
  • Importance of different medical affairs resources/approaches for successful new product entry
  • Importance of different marketing resources/approaches for successful new product entry
  • Importance of different sales resources/approaches for successful new product entry
  • Importance of different supply chain/technical support resources/approaches for successful new product entry

SAMPLE KEY FINDINGS

  • Market Entry Requires Investing At and Above Market Leader Levels To Win Share of Voice: More than half of the Total Benchmark Class – 64 percent - favors spending 101 percent to 150 percent of the market leader’s investment level during product launch.

METHODOLOGY

The benchmark class includes participation from 44 executives at 38 leading pharmaceutical, biotech and health-care companies. Nine metabolic leaders participated in this study although the level of their participation varied across the question set.


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.